Ramakrishnan MS, et al. - In the present study, the researchers sought to quantify the connection between patients’ adherence to randomized clinical trial visits and visual acuity (VA) in people with neovascular age-related macular degeneration based on 4 visit adherence metrics. Participants in the study were 1,178 patients [mean (SD) age was 79.1 (7.3) years]. Study participants were expected to attend visits every 4 weeks. Each missed visit was related to an average VA letter score decline of 0.7. Patients who averaged between 36 and 60 days and more than 60 days between visits lost 6.1 and 12.5 letters, respectively, as opposed to patients who were on time. Adherence to visits can lead to VA outcomes in neovascular age-related macular degeneration.